---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Place in treatment, anticipated use, and care setting. Topics: Anticipated population: patients aged 2 years and older, Anticipated use: U.S. patient estimate and market research, Care setting: one-time outpatient intrathecal administration, Payer research: value proposition of a one-time outpatient administration, and 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Anticipated population: patients aged 2 years and older

> “The TSHA-102 clinical development program is designed to support the potential future approval for a broad population of patients aged 2 years and older with Rett syndrome through an efficient and rigorously designed pathway.”
> “Taysha designed the TSHA-102 pivotal program so that efficacy data from the REVEAL Pivotal Trial in participants aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE Trial to support a broad label for TSHA-102.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="topic-2.2.2.2-2"></a>

### Anticipated use: U.S. patient estimate and market research

> “Within the U.S. specifically, patient estimates range from 6,000 to 9,000 based on claims data and epidemiology data. Completed U.S. market research demonstrates strong clinician and caregiver demand and anticipated broad adoption of TSHA-102 across pediatric, adolescent and adult patients with Rett syndrome. The research also indicates a clear preference for intrathecal administration, which is viewed as familiar, accessible and scalable, enabling the potential to safely and efficiently treat patients across institutions.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.2.2-3"></a>

### Care setting: one-time outpatient intrathecal administration

> “Routine outpatient procedure enables scalable access beyond COEs, with ~75% of patients managed outside large Rett COEs”
> “Strong preference for IT delivery over direct-to-brain due to familiarity, accessibility and scalability”
> “Delivered intrathecally as a routine, minimally invasive procedure with outpatient potential, enabling broad, scalable access”

Source: [Taysha Gene Therapies August 2026 corporate presentation (2026)](https://ir.tayshagtx.com/static-files/8da485f7-d48d-42b8-8fa7-388d58d55487)

<a id="topic-2.2.2.2-4"></a>

### Payer research: value proposition of a one-time outpatient administration

> “TSHA-102 was viewed as a high-value therapy due to its transformative disease-modifying potential in a population with high unmet need, combined with the convenience of a one-time IT administration that can be performed in an outpatient setting”
> “Strong efficacy, safety and durability are expected to drive coverage and reimbursement, with durable functional benefits serving as the key value determinant in this high unmet need setting”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="topic-2.2.2.2-5"></a>

### Route of administration: intrathecal lumbar compared with intracerebroventricular delivery

> “Administration route strongly influences biodistribution: ICV delivery (NGN-401) provides broad brain penetration but requires neurosurgery, whereas intrathecal lumbar injection (TSHA-102) is less invasive but may yield more limited forebrain distribution.”
> “ICV delivery requires neurosurgical placement of a catheter into the lateral ventricle”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.2-6"></a>

### Role of neurologists and specialized centers

> “As these therapies progress toward potential regulatory approval, neurologists will play central roles in identifying eligible patients, counseling families, supporting clinical trial enrollment, delivering treatments, monitoring long-term outcomes, and advocating for equitable access.”
> “Access is further constrained by the need for specialized centers capable of administering therapy and monitoring for complications, disproportionately affecting families in rural areas, underserved communities, and low-income countries.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.2-7"></a>

### Current access: clinical trial participation only

> “Access to Taysha’s investigational products is currently available only through participation in a clinical trial for patients who meet the applicable eligibility criteria.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
